8-chloro-11-(4-methyl-1-piperazinyl)-5H- dibenzo[b,e][1,4]diazepine N-oxide | 1347975-16-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 8-chloro-11-(4-methyl-1-piperazinyl)-5H- dibenzo[b,e][1,4]diazepine N-oxide
• 英文别名: clozapine-N-oxide；Clozapine 5-oxide；3-chloro-6-(4-methylpiperazin-1-yl)-11-oxido-11H-benzo[b][1,4]benzodiazepin-11-ium
• CAS: 1347975-16-9
• 化学式: C₁₈H₁₉ClN₄O
• 分子量: 342.828
• InChiKey: VIYZIEMPGBOGLI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  40.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氯氮平 在 recombinant human CYP₂J₂ 、 还原型辅酶II(NADPH)四钠盐 作用下， 以 aq. phosphate buffer 为溶剂， 生成 8-chloro-11-(4-methyl-1-piperazinyl)-5H- dibenzo[b,e][1,4]diazepine N-oxide
  参考文献：
  名称：

  CYP-catalysed cycling of clozapine and clozapine- N -oxide promotes the generation of reactive oxygen species in vitro

  摘要：

  DOI：

  10.1080/00498254.2023.2294473

文献信息

• USE OF HM4DI IN THE TREATMENT OF SEIZURE DISORDERS
  申请人：Ovid Therapeutics Inc.

  公开号：EP3710010A1

  公开（公告）日：2020-09-23
• USE OF hM4Di IN THE TREATMENT OF SEIZURE DISORDERS
  申请人：Ovid Therapeutics Inc.

  公开号：US20190184034A1

  公开（公告）日：2019-06-20

  Methods and compositions for treating a seizure disorder are provided which include administering to the patient an adeno-associated virus vector encoding hM4Di for delivery of hM4Di to a target location, the vector including a human or murine CaMKII promoter, a woodchuck hepatitis virus post-transcriptional regulatory element, and a bovine growth hormone polyadenylation sequence, and administering to the patient a synthetic ligand which activates hM4Di. Administration of the vector and synthetic ligand to a patient with a seizure disorder is associated with reduced symptoms of the seizure disorder. In embodiments, ultrasound is applied to a target location in the patient's brain to enhance permeability of the patient's blood brain barrier to the vector and/or synthetic ligand.
• [EN] USE OF DESIGNER RECEPTORS EXCLUSIVELY ACTIVATED BY DESIGNER DRUGS IN THE TREATMENT OF SEIZURE DISORDERS<br/>[FR] UTILISATION DE RÉCEPTEURS SUR MESURE EXCLUSIVEMENT ACTIVÉS PAR DES MÉDICAMENTS SUR MESURE DANS LE TRAITEMENT DE TROUBLES ÉPILEPTIQUES
  申请人：OVID THERAPEUTICS INC

  公开号：WO2018170223A1

  公开（公告）日：2018-09-20

  Methods and compositions for treating a seizure disorder are provided which include administering to the patient a vector encoding a modified receptor for delivery of the modified receptor to the target location, the modified receptor being modified to be activated by a synthetic ligand, wherein the modified receptor inhibits neuronal firing when activated; and administering to the patient the synthetic ligand. Also provided are methods and compositions for treating a seizure disorder in a patient in need thereof by administering to the patient a vector encoding a modified receptor for delivery of the modified receptor to the target location, the modified receptor being modified to be activated by a synthetic ligand, wherein the modified receptor increases neuronal firing when activated; and administering to the patient the synthetic ligand. The methods are used to improve or alleviate one or more symptoms of a seizure disorder.